Table 1 Demographic and laboratory data of patients at the beginning of the study
Variables | Number = 334 |
|---|---|
Age (years) | 41.69 ± 9.67 |
BMI | 22.02 ± 2.96 |
Male gender (N, %) | 191 (57.2%) |
Female gender (N, %) | 143 (42.8%) |
Duration of dialysis (months) | 34.07 ± 17.41 |
HCV genotype IV viremia (IU/ml) | |
Low viremia less than 200,000 IU/mL (N, %) | 79 (23.7%) |
Moderate viremia 200,000–2,000,000 IU/mL (N, %) | 155 (46.4%) |
High viremia more than 2,000,000 IU/mL (N, %) | 100 (29.9%) |
Laboratory data before HCV treatment (mean ± SD) | |
Hemoglobin (12–15.5 g/dL) | 9.8 ± 1.8 |
WBCs (4.5–11 × 109/ml) | 9.8 ± 5 |
Uric acid (2.4–6 mg/dl) | 5.5 ± 1.8 |
ALT (up to 35 IU/L) | 37.9 ± 22.1 |
Serum albumin (3.4–5.4 g/L) | 3.2 ± 0.5 |
PT (11–13.5 s) | 13.1 ± 1.1 |
Corrected calcium (8.6–10.2 mg/dl) | 8.2 ± 0.8 |
Phosphorous (3–4.5 mg/dl) | 5.1 ± 0.8 |
Serum parathormone (10–55 pg/mL) | 358.3 ± 177 |
TSAT% | 18.8 ± 9.6 |
Ferritin (20–250 ng/ml) | 333.75 ± 377.41 |
FGF23 Level (< 180 µ/ml) | 256.4 ± 24.2 |
CRP (up to 6 mg/dl) | 3.377 ± 4.27 |
Single pool Kt/V (1.2) | 1.55 ± 0.36 |